Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $472000.0 in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 31.84% year-over-year to $472000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 million (up 19.24% YoY) and the FY2025 annual result came in at $1.6 million, down 8.32% from the prior year.
• Depreciation & Amortization (CF) advanced to $472000.0 in Q2 2026, from $468000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $656000.0 in Q1 2022 to a low of $345000.0 in Q1 2025.
• A 5-year average of $496222.2 and a median of $470000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 110.26% — and 2024, when it slumped 33.83%.
• Tracing KNSA's Depreciation & Amortization (CF) over 5 years: stood at $602000.0 in 2022, then dropped by 10.3% to $540000.0 in 2023, then declined by 25.93% to $400000.0 in 2024, then gained by 16.75% to $467000.0 in 2025, then increased by 1.07% to $472000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $472000.0 (Q2 2026), $468000.0 (Q1 2026), and $467000.0 (Q4 2025), per Business Quant data.